Health Care Related Organization
FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy
Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology
WHO Prequalifies Bavarian Nordic’s MVA-BN Vaccine as First Mpox Vaccine
WHO, mpox vaccine, Bavarian Nordic, MVA-BN, prequalification, global health, vaccine access
Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options
Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology
Biopharma Layoff Tracker 2024: Ongoing Industry Downsizing
Biopharma layoffs, 2024 layoffs, pharmaceutical industry downsizing, biotech job cuts, pharma restructuring
Sanofi’s $1 Billion Bet on Muscular Dystrophy Drug Falters, Fulcrum Shares Plummet
Sanofi, Fulcrum, muscular dystrophy drug, pharmaceutical failure, stock market impact
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences
Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity
Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results
Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors